Skip to content
TrialScanner

NCT03589339

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Phase 1Active, not recruitingNBTXLead

Registry record

Lead sponsor
Nanobiotix
Conditions
Radiotherapy; Immunotherapy; Microsatellite Instability-High Solid Malignant Tumour; Metastasis From Malignant Tumor of Liver; Squamous Cell Carcinoma of Head and Neck
Primary completion
Apr 30, 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT03589339 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03589339: NBTXR3 Activated by Radiother... | TrialScanner